Thursday May 17, 8:31 am Eastern Time
Press Release
SOURCE: AtheroGenics, Inc.
CONFERENCE CALL ALERT: AtheroGenics, Inc. (Nasdaq: AGIX) Invites
You To Participate in a Conference Call on May 21, 2001
ATLANTA, May 17 /PRNewswire/ -- A conference call with AtheroGenics, Inc. has been arranged to discuss the top-line
results of the company's CART-1 Phase II clinical study for their lead compound, AGIX-1067, an oral agent for the treatment
of post-angioplasty restenosis.
Russell M. Medford, MD, PhD, President and Chief Executive Officer, Mitchell Glass, MD, Senior Vice President of Strategic
Drug Development and Mark P. Colonnese, Vice President of Finance & Administration and Chief Financial Officer, will host
the call.
DATE: Monday, May 21, 2001
TIME: 9:00 a.m. EDT
CONFERENCE CALL DIAL-IN: 1-800-360-9865
INTERNATIONAL CALLERS, PLEASE DIAL: 1-973-694-6836
CONFERENCE CALL PASSWORD: AtheroGenics
A playback of the call will be available from 11:00 a.m. EDT, May 21, 2001
to 11:00 p.m. EDT, June 1, 2001
Playback dial-in number: 1-800-428-6051, pin number 191637
International callers, please dial: 1-973-709-2089, pin number 191637
SOURCE: AtheroGenics, Inc. |
